TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Natixis Advisors LLC

Natixis Advisors LLC increased its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 42.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,547 shares of the biopharmaceutical company’s stock after buying an additional 12,065 shares during the period. Natixis Advisors LLC’s holdings in TG Therapeutics were worth $1,599,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. Soleus Capital Management L.P. raised its position in shares of TG Therapeutics by 5.8% in the fourth quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company’s stock valued at $80,705,000 after buying an additional 146,702 shares during the last quarter. Northern Trust Corp raised its position in shares of TG Therapeutics by 8.6% in the fourth quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company’s stock valued at $46,141,000 after buying an additional 120,785 shares during the last quarter. Invesco Ltd. raised its position in shares of TG Therapeutics by 1.2% in the fourth quarter. Invesco Ltd. now owns 929,743 shares of the biopharmaceutical company’s stock valued at $27,985,000 after buying an additional 10,989 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of TG Therapeutics by 1.3% in the first quarter. Principal Financial Group Inc. now owns 841,011 shares of the biopharmaceutical company’s stock valued at $33,161,000 after buying an additional 10,827 shares during the last quarter. Finally, Braun Stacey Associates Inc. raised its position in shares of TG Therapeutics by 13.5% in the first quarter. Braun Stacey Associates Inc. now owns 502,650 shares of the biopharmaceutical company’s stock valued at $19,819,000 after buying an additional 59,845 shares during the last quarter. Institutional investors and hedge funds own 58.58% of the company’s stock.

Insider Transactions at TG Therapeutics

In other news, Director Yann Echelard sold 10,000 shares of the stock in a transaction on Friday, June 13th. The shares were sold at an average price of $36.94, for a total value of $369,400.00. Following the completion of the sale, the director owned 228,816 shares of the company’s stock, valued at $8,452,463.04. This represents a 4.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.64% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group raised shares of TG Therapeutics to a “hold” rating and set a $37.00 price objective for the company in a research report on Thursday, July 10th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $46.25.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $26.71 on Friday. TG Therapeutics, Inc. has a one year low of $19.45 and a one year high of $46.48. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.04 and a current ratio of 4.02. The company has a 50 day moving average price of $36.10 and a 200 day moving average price of $35.95. The firm has a market capitalization of $4.24 billion, a price-to-earnings ratio of 72.19 and a beta of 1.95.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.15). TG Therapeutics had a return on equity of 27.83% and a net margin of 13.31%. The company had revenue of $141.15 million for the quarter, compared to analyst estimates of $147.76 million. During the same period last year, the company posted $0.04 EPS. The business’s revenue for the quarter was up 92.1% on a year-over-year basis. Sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.